FrancophonIA/ELRC3.0 huggingface dataset:
English: You will also have blood tests and be weighed regularly.
Estonian: Imatinib Accord'i kasutamise ajal tehakse regulaarselt vereanalüüse ja teie kehakaalu kontrollitakse korrapäraselt.
English: • Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
Estonian: • Lööve, nahapunetus koos villidega huultel, silmadel, nahal või suus, naha koorumine, palavik,
English: ARA-C (3 g/m2/dose q 12 h x 4, IV): days 2 and 3
Estonian: Kolmekordne IT ravi (vanusele kohandatud): 1. päeval ARA-C (3 g/m2/annus q 12 h x 4, IV): päevadel 2 ja 3
English: Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81%
Estonian: Pärast imatiniibi 14Cmärgistatud suukaudset annust leiti 7 päeva jooksul ligikaudu 81% annusest,
English: This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to Imatinib.
Estonian: Tulemusnäitajat - haiguse progresseerumiseni kuluvat aega - mõjutab oluliselt suur IFN+Ara-C ravilt imatiniib-ravile üleviimise sagedus.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 400 mg imatinib (as mesilate)
Estonian: TOIMEAINE(TE) SISALDUS Üks õhukese polümeerkattega tablett sisaldab 400 mg imatiniibi (mesilaadina).
English: If you are being treated for Ph-positive ALL The starting dose is 600 mg to be taken as 6 tablets of 100 mg or one tablet of 400 mg plus 2 tablets of 100 mg once a day.
Estonian: 600 mg, mis võetakse kuue 100 mg tabletina või ühe 400 mg tabletina pluss kahe 100 mg tabletina üks kord ööpäevas.
English: VCR 2 mg total dose i.v., days 1, 8, 15, 22; CP 750 mg/m2 i.v., days 1, 8;
Estonian: Ara-C 40 mg intratekaalselt, päevadel 1, 8, 15, 22; metüülprednisoloon 40 mg intratekaalselt, päevadel 1, 8, 15, 22
English: DATE OF REVISION OF THE TEXT
Estonian: Konsolidatsioonravi
English: NAME OF THE MEDICINAL PRODUCT Imatinib Accord 100 mg film-coated tablets imatinib
Estonian: RAVIMPREPARAADI NIMETUS Imatinib Accord 100 mg õhukese polümeerkattega tabletid Imatiniib
English: NAME OF THE MEDICINAL PRODUCT Imatinib Accord 400 mg film-coated tablets imatinib
Estonian: RAVIMPREPARAADI NIMETUS Imatinib Accord 400 mg õhukese polümeerkattega tabletid Imatiniib
English: Posology for HES/CEL
Estonian: Annustamine HES/KEL korral
English: (1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/ m2 oral, days 26-46
Estonian: (1 h), päevadel 28...31, 35...38, 42...45;
English: If your daily dose is 800 mg (8 tablets of 100 mg or 2 tablets of 400 mg).
Estonian: Kui teie ööpäevaseks annuseks on 800 mg (kaheksa 100 mg tabletti või kaks 400 mg tabletti), peaksite võtma neli 100 mg tabletti või ühe 400 mg tableti hommikul ja neli 100 mg tabletti või ühe 400 mg tableti õhtul.
English: DEX 10 mg/ m2 oral, days 1-5; CP 200 mg/ m2 i.v., days 3-5; MTX 15mg intrathecal, day 1
Estonian: DEX 10 mg/m2 suukaudselt, päevadel 1...5; CP 200 mg/m2 i.v., päevadel 3...5;
English: Pericarditis*, cardiac tamponade* Vascular disorders4
Estonian: Periorbitaalne turse, dermatiit/ekseem/lööve
English: (NEL) Return to chronic phase
Estonian: Ei ole kohaldatav puudumine Kroonilise staadiumi
English: Blood and lymphatic system disorders Very common Neutropenia, thrombocytopenia, anaemia Common
Estonian: Anafülaktiline šokk* Vere ja lümfisüsteemi häired Väga sage
English: A total of 51 paediatric patients with newly diagnosed and untreated CML in chronic phase have been enrolled in an open-label, multicentre, single-arm phase II trial.
Estonian: Avatud mitmekeskuselises, ühe haruga II faasi uuringus osales 51 kroonilises faasis KML esmakordse diagnoosiga last, kes varem ei olnud saanud ravi.
English: Dose increases from 340 mg/m2 daily to 570 mg/m2 daily (not to exceed the total dose of 800 mg) may be considered in children and adolescents in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
Estonian: (igal ajal); rahuldava hematoloogilise vastuse puudumine pärast vähemalt kolm kuud kestnud ravi; tsütogeneetilise vastuse puudumine pärast 12-kuulist ravi või eelneva raviga saavutatud hematoloogilise ja/või tsütogeneetilise vastuse kadumine.
English: Musculoskeletal and connective tissue disorders Very common Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia,
Estonian: Lihasspasmid ja -krambid, skeletilihaste valu, sh lihasvalu9, liigesvalu, luuvalu10
English: Daunorubicin 45 mg/ m2 i.v., days 6-7, 13-14
Estonian: 6-MP 60 mg/m2 suukaudselt, päevadel 26...46
English: CPM (250 mg/m2/dose q12h x 4 doses, IV): days 3 and 4 PEG-ASP (2500 IUnits/m2, IM): day 4
Estonian: DAUN (45 mg/m2/ööpäev boolusena, IV): päevadel 1 ja 2 CPM (250 mg/m2/anus q12h x 4 annust, iv): päevadel 3 ja 4 PEG-ASP (2500 RÜ/m2, IM): 4. päev G-CSF (5 μg/kg, SC): päevadel 5...14 või kuni neutrofiilide absoluutarv > 1500 üle minimaalse väärtuse Kolmekordne IT ravi (vanusele kohandatud): päevadel 1 ja 15 DEX (6 mg/m2/ööpäev, PO): päevadel 1...7 ja 15...21
English: There are no controlled trials in paediatric patients with MDS/MPD.
Estonian: MDS/MPD diagnoosiga lastel ei ole kontrollitud kliinilisi uuringuid läbi viidud.
English: Occurrences of severe fluid retention (pleural effusion, oedema, pulmonary oedema, ascites, superficial oedema) have been reported in approximately 2.5% of newly diagnosed CML patients taking imatinib.
Estonian: Ligikaudu 2,5% imatiniibi kasutavast esmakordselt diagnoositud KML patsiendist on täheldatud rasket vedelikupeetust (pleura efusioon, tursed, kopsuturse, astsiit, pindmine turse).
English: MTX 12 mg intrathecal, day 1 Remission induction DEX 10 mg/ m2 oral, days 6-7, 13-16;
Estonian: DEX 10 mg/m2 suukaudselt, päevadel 6...7, 13...16;
English: 16 December 2016 EMA/822770/2016 EMEA/H/C/004023
Estonian: 16. detsember 2016 EMA/822770/2016 EMEA/H/C/004023
English: What is Efgratin?
Estonian: Mis on Efgratin?
English: On 16 November 2016, Gedeon Richter Plc officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Efgratin, for reducing neutropenia.
Estonian: Ettevõte Gedeon Richter Plc teatas 16. novembril 2016 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Efgratin müügiloa taotlus.
English: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim) EMA/822770/2016
Estonian: Müügiloa taotluse tagasivõtmise teave: Efgratin (pegfilgrastiim) EMA/822770/2016
English: A further study in patients receiving cancer medicines compared the safety and effectiveness of Efgratin and Neulasta.
Estonian: Teises uuringus, milles osalesid vähiravimeid saanud patsiendid, võrreldi Efgratini ja Neulasta ohutust ja efektiivsust.
English: This means that Efgratin was intended to be highly similar to a biological medicine (the ‘reference medicine') already authorised in the European Union called Neulasta.
Estonian: See tähendab, et Efgratin pidi olema sarnane bioloogilise ravimiga (võrdlusravimiga) Neulasta, millel juba on Euroopa Liidus müügiluba.
English: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)
Estonian: Müügiloa taotluse tagasivõtmise teave: Efgratin (pegfilgrastiim)
English: How does Efgratin work?
Estonian: Kuidas Efgratin toimib?
English: The company presented results of studies in healthy people designed to show that Efgratin is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine.
Estonian: Ettevõte esitas tulemused tervetel inimestel tehtud uuringutest, mille eesmärk oli näidata, et Efgratin on keemilise struktuuri, puhtuse, toimemehhanismi ja organismis metaboliseerumise poolest sarnane võrdlusravimiga Neulasta.
English: Efgratin was developed as a ‘biosimilar' medicine.
Estonian: Efgratin töötati välja bioloogiliselt sarnase ravimina.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Efgratin could not have been approved for reducing neutropenia.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et Efgratini ei saa neutropeenia vähendamiseks heaks kiita.
English: The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for Efgratin.
Estonian: Ettevõte teatas inimravimite komiteele, et Efgratiniga ei viida läbi kliinilisi uuringuid ega eriloaga kasutamise programme.
English: Efgratin was to be used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever).
Estonian: Efgratini kavatseti kasutada neutropeenia kestuse ja febriilse neutropeenia (palavikuga neutropeenia) esinemissageduse vähendamiseks.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not demonstrated that Efgratin is highly similar to Neulasta.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ettevõte ei olnud tõendanud Efgratini sarnasust Neulastaga.
English: The CHMP was concerned that study results had not shown that Efgratin was handled by the body in the same way as the reference medicine Neulasta.
Estonian: Inimravimite komiteed tegi ettevaatlikuks asjaolu, et uuringutulemused ei tõendanud, kas organism metaboliseerib Efgratini samal viisil kui võrdlusravimit Neulasta.
English: Efgratin is a medicine that contains the active substance pegfilgrastim, which stimulates the production of neutrophils (a type of white blood cell that fights infections).
Estonian: Efgratin on toimeainena pegfilgrastiimi sisaldav ravim, mis stimuleerib neutrofiilide (teatud infektsioonivastaste valgeliblede) teket.
English: The active substance in Efgratin, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol).
Estonian: Efgratini toimeaine pegfilgrastiim koosneb pegüleeritud (polüetüleenglükooliga (PEG) kaetud) filgrastiimist.
English: What was Efgratin expected to be used for?
Estonian: Milleks kavatseti Efgratini kasutada?
English: Efgratin was to be used in cancer patients to reduce neutropenia (low levels of neutrophils).
Estonian: Efgratini kavatseti kasutada neutropeenia (neutrofiilide vähesuse) vähendamiseks vähipatsientidel.
English: The full EPAR for Abraxane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Abraxane kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A response was defined as the patient's main tumours disappearing or shrinking in size by at least 30%.
Estonian: Ravivastus määratleti patsiendi põhikasvaja kadumisena või suuruse vähenemisena vähemalt 30% võrra.
English: What measures are being taken to ensure the safe and effective use of Abraxane?
Estonian: Mis meetmed võetakse, et tagada Abraxane ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Abraxane on 11 January 2008.
Estonian: Euroopa Komisjon andis Abraxane müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. jaanuaril
English: A risk management plan has been developed to ensure that Abraxane is used as safely and effectively as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Abraxane võimalikult ohutu kasutamine.
English: This makes it easy to prepare a suspension of paclitaxel, which can be infused into a vein.
Estonian: Tänu sellele on kergem valmistada paklitakseeli suspensiooni, mida saab infusiooniga manustada veeni.
English: By keeping this structure intact the cells cannot divide and they eventually die.
Estonian: Kui raku sisetoes püsib, ei saa rakk jaguneda ning lõpuks hävib.
English: Other information about Abraxane
Estonian: Muu teave Abraxane kohta
English: The Committee decided that Abraxane's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Abraxane kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: The recommended dose is 260 mg per square metre of body surface area (calculated using the patient's height and weight).
Estonian: Soovitatav annus on 260 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kehamassi järgi).
English: The recommended dose is 125 mg per square metre of body surface area once a day on days 1, 8 and 15 of each cycle.
Estonian: Soovitatav annus on 125 mg kehapinna ruutmeetri kohta üks kord ööpäevas tsükli 1., 8. ja 15. päeval.
English: The most common important side effects with Abraxane (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, a type of white blood cells), gastrointestinal disorders (disorders of the digestive system), peripheral neuropathy (nerve damage including damage to the nerves in the hand and feet), arthralgia (joint pain) and myalgia (muscle pain).
Estonian: Abraxane kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on neutropeenia (neutrofiilide (teatud tüüpi valgeliblede) vähene sisaldus), gastrointestinaalsed häired (seedetraktihäired), perifeerne neuropaatia (närvikahjustused, sh kätel ja jalgadel), artralgia (liigesevalu) ja müalgia (lihasevalu).
English: The main measure of effectiveness was the percentage of patients who responded to treatment.
Estonian: Efektiivsuse põhinäitaja oli ravile reageerinud patsientide protsent.
English: Around half of the patients in the study had already received treatments for their cancer after it had become metastatic.
Estonian: Ligikaudu pool uuringus osalenud patsientidest oli saanud vähiravi pärast metastaaside tekkimist.
English: Therefore, the company withdrew its application for the use of Abraxane as firstline treatment during the assessment of the medicine.
Estonian: Ettevõte võttis seepärast ravimi hindamise käigus tagasi oma taotluse Abraxane kasutamiseks esmavaliku ravimina.
English: Abraxane also affects non-cancer cells such as blood and nerve cells, which can cause side effects.
Estonian: Abraxane mõjub ka muudele rakkudele peale vähirakkude, näiteks vere- ja närvirakkudele, mis võib põhjustada kõrvalnähte.
English: The main measure of effectiveness was the number of patients who ‘responded' after at least five weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis ravivastus pärast vähemalt 5-nädalast ravi.
English: Overall, in the main study, 31% of the women receiving Abraxane responded to treatment (72 out of 229), compared with 16% of the women receiving conventional paclitaxel-containing medicines (37 out of 225).
Estonian: Ravivastusega naisi oli põhiuuringus Abraxane rühmas 31% (72 patsienti 229st) ja tavapäraseid paklitakseeli sisaldavaid ravimeid kasutanud rühmas 16% (37 patsienti 225st).
English: For more information about treatment with Abraxane, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Abraxanega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Abraxane?
Estonian: Mis on Abraxane?
English: This document is a summary of the European Public Assessment Report (EPAR) for Abraxane.
Estonian: See on ravimi Abraxane Euroopa avaliku hindamisaruande kokkuvõte.
English: Abraxane must not be used in patients who are breast-feeding or who have low levels of neutrophils in the blood before starting treatment.
Estonian: Abraxanet ei tohi kasutada patsiendid, kes imetavad last või kelle vere neutrofiilisisaldus on enne ravi alustamist väike.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Abraxane.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The main measure of effectiveness was how long patients lived.
Estonian: Efektiivsuse põhinäitaja oli patsientide elulemus.
English: For metastatic breast cancer, Abraxane has been studied in one main study involving 460 women, around three-quarters of whom had received an anthracycline in the past.
Estonian: Abraxane toimet metastaatilisele rinnavähile uuriti ühes põhiuuringus, milles osales 460 naist, kellest ligikaudu kolmveerand olid varem saanud antratsükliini.
English: The recommended dose of Abraxane is 100 mg per square metre of body surface area.
Estonian: Abraxane soovitatav annus on 100 mg kehapindala ruutmeetri kohta.
English: What is the risk associated with Abraxane?
Estonian: Mis riskid Abraxanega kaasnevad?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abraxane, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Abraxane omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In non-small cell lung cancer, treatment is carried out in 3-week cycles with Abraxane given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Abraxane.
Estonian: Mitteväikerakk-kopsuvähi korral manustatakse Abraxanet 3-nädalaste ravitsüklitena: Abraxanet manustatakse tsükli 1., 8. ja 15. päeval; 1. päeval vahetult pärast Abraxanet manustatakse ka karboplatiini.
English: Why has Abraxane been approved?
Estonian: Miks Abraxane heaks kiideti?
English: Immediately after giving Abraxane gemcitabine should be given at a dose of 1000 mg per square metre of body surface area.
Estonian: Vahetult pärast Abraxanet tuleb manustada gemtsitabiini annuses 1000 mg kehapinna ruutmeetri kohta.
English: Abraxane is used to treat the following cancers in adults:
Estonian: Abaxanet kasutatakse täiskasvanutel järgmiste vähivormide raviks.
English: • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.
Estonian: • Mitteväikerakk-kopsuvähi esmaravimina koos vähiravimi karboplatiiniga, kui ei saa kasutada operatsiooni ega kiiritusravi.
English: Paclitaxel blocks a stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide.
Estonian: Paklitakseel blokeerib rakkude jagunemisel etapi, kus raku sisetoes rakkude jagunemiseks laguneb.
English: • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline' (another type of cancer medicine) is not suitable.
Estonian: • Metastaatiline rinnavähk, kui esmaravi enam ei mõju ja standardravi antratsükliiniga (teist tüüpi vähiravim) ei sobi.
English: The CHMP noted that Abraxane was more effective than conventional paclitaxel-containing medicines in patients with metastatic breast cancer whose first treatment had stopped working, and that, unlike other paclitaxel-containing medicines, patients to be treated with Abraxane do not need pre-treatment with other medicines to prevent hypersensitivity reactions.
Estonian: Inimravimite komitee märkis, et Abraxane oli tavapärastest paklitakseeli sisaldavatest ravimitest efektiivsem nende metastaatilise rinnavähiga patsientide ravimisel, kellele esmavaliku ravim enam ei mõju, ning et erinevalt teistest paklitakseeli sisaldavatest ravimitest ei vaja Abraxanet saavad patsiendid eelravi teiste ravimitega, et vähendada ülitundlikkusreaktsioone.
English: Patients survived for around 8.5 months on treatment with the combination of Abraxane and gemcitabine, compared with 6.7 months on gemcitabine alone.
Estonian: Abraxanet ja gemtsitabiini kasutanud patsiendid elasid ligikaudu 8,5 kuud, ja ainult gemtsitabiini kasutanud patsiendid 6,7 kuud.
English: For metastatic adenocarcinoma of the pancreas, Abraxane was studied in one main study involving 861 patients who received either Abraxane in combination with gemcitabine or gemcitabine alone.
Estonian: Abraxane toimet pankrease metastaatilisele adenokartsinoomile uuriti ühes põhiuuringus 861 patsiendil, kellele manustati kas Abraxanet koos gemtsitabiiniga või ainult gemtsitabiini.
English: For additional information, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
English: In non-small cell lung cancer, 33% of patients receiving Abraxane and carboplatin responded to treatment compared with 25% of those receiving conventional paclitaxel and carboplatin.
Estonian: Mitteväikerakk-kopsuvähi korral oli ravivastusega patsiente Abraxane ja karboplatiini kasutanud patsiendirühmas 33% ning tavapärase paklitakseeli ja karboplatiini rühmas 25%.
English: Abraxane is given into a vein over a period of 30 minutes.
Estonian: Abraxanet manustatakse veeni 30 minutit kestva infusioonina.
English: In metastatic breast cancer, Abraxane was more effective than conventional paclitaxel-containing medicines.
Estonian: Metastaatilise rinnavähi korral oli Abraxane tavapärastest paklitakseeli sisaldavatest ravimitest efektiivsem.
English: It contains the active substance paclitaxel attached to a human protein called albumin.
Estonian: Ravim sisaldab toimeainena inimvalgu albumiiniga seotud paklitakseeli.
English: Abraxane should only be given under the supervision of a specialist cancer doctor in units that are specialised in giving ‘cytotoxic' (cell-killing) medicines.
Estonian: Abraxanet tohib kasutada ainult onkoloogi järelevalve all tsütotoksiliste (rakke hävitavate) ravimite manustamisele spetsialiseerunud osakonnas.
English: Abraxane is a powder that is made up into a suspension for infusion (drip) into a vein.
Estonian: Abraxane on infusioonisuspensiooni (veeni tilgutatava suspensiooni) pulber.
English: It should not be interchanged with other medicines containing paclitaxel.
Estonian: Abraxanet ei tohi asendada teiste paklitakseeli sisaldavate ravimitega.
English: When looking only at the patients who were receiving their first treatment for metastatic breast cancer, there was no difference between the medicines in terms of measures of effectiveness such as the time until the disease got worse and survival.
Estonian: Patsientidel, kellel raviti metastaatilist rinnavähki esimest korda, puudus ravimite efektiivsuse erinevus (haiguse süvenemiseni kulunud aja ja elulemuse järgi).
English: In addition, Abraxane given in combination with gemcitabine was shown to improve survival in patients with metastatic adenocarcinoma of the pancreas compared with treatment with gemcitabine alone and was effective in combination with carboplatin in the treatment non-small cell lung cancer.
Estonian: Lisaks tõendati, et kombinatsioonis gemtsitabiiniga kasutatud Abraxane suurendas pankrease metastaatilise adenokartsinoomiga patsientide elulemust võrreldes ainult gemtsitabiiniga, samuti oli Abraxane ja karboplatiini kombinatsioon efektiivne mitteväikerakk-kopsuvähi ravis.
English: Abraxane given on its own was compared with a conventional paclitaxel-containing medicine given together with other medicines to reduce side effects.
Estonian: Abraxane kasutamist ainsa ravimina võrreldi tavapärase paklitakseeli sisaldava ravimiga, mida kasutati koos teiste ravimitega, et vähendada kõrvalnähte.